GT Biopharma (NASDAQ:GTBP) Now Covered by Analysts at Roth Mkm
Roth Mkm started coverage on shares of GT Biopharma (NASDAQ:GTBP – Free Report) in a report published on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $11.00 price target ...
Surface protein study highlights a potential link between dental caries and renal lesions
IgA nephropathy (IgAN) is an immune response disease affecting the filtering units of the kidneys. It is an intractable ...